DNase for cystic fibrosis patients with mild to moderate lung disease

Christopher F, Chase D, Milne R
Record ID 31999008494
Authors' objectives:

To assess the effectiveness and cost-effectiveness of DNase in treating cystic fibrosis.

Authors' recommendations: The use of DNase for cystic fibrosis was addressed in a previous DEC report in 1994 (Report No. 17), when the committee's decision was "not proven". The committee has now concluded that there is high quality evidence for the short term benefits of DNase over a period of six months. However, at present the only evidence supporting DNase in the longer term is from the modelling presented in this DEC report, which is based upon a number of uncertain assumptions. The committee did not feel able to base a decision upon this modelling, and concluded that the use of DNase in the long-term is not proven. Treatment with DNase is often likely to be longer term than that seen in clinical trials. It should be guided by protocols which seek to target therapy at those who benefit most. The guidelines from the former South and West Region, which limit DNase treatment to those patients with an FEV1 of less than or equal to 70% of predicted, and who also demonstrate a sustained improvement in FEV1 of more than 10% after a trial period, are a useful example.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1999
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Costs and Cost Analysis
  • Cystic Fibrosis
  • Deoxyribonucleases
  • Lung Diseases
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.